COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 2148: Articles 21471-21480  | Next

The power and limitations of genomics to track COVID-19 outbreaks: a case study from New Zealand
Geoghegan, J. L., Douglas, J., Ren, X., Storey, M., Hadfield, J., Silander, O. K., Freed, N. E., Jelley, L., Jefferies, S., Sherwood, J., Paine, S., Huang, S., Sporle, A., Baker, M. G., Murdoch, D. R., Drummond, A. J., Welch, D., Simpson, C. R., French, N., Holmes, E. C., de Ligt, J.
10.1101/2020.10.28.20221853 — Posted: 2020-11-03
Residual SARS-CoV-2 viral antigens detected in gastrointestinal and hepatic tissues from two recovered COVID-19 patients
Cheung, C. C. L., Goh, D., Lim, X., Tien, T. Z., Lim, J. C. T., Nerurkar, S. N., Loong, S., Cheow, P. C., Chan, C. Y., Koh, Y. X., Tan, T. T., Kalimuddin, S., Tai, W. M. D., Ng, J. L., Low, J. G. H., Yeong, J., Lim, T. K. H.
10.1101/2020.10.28.20219014 — Posted: 2020-11-03
Sample pooling, a population screening strategy for SARS-CoV2 to prevent future outbreak and mitigate the second-wave of infection of the virus
Sawarkar, S. S., Victor, A., Viotti, M., Haran, S. P., Verma, S., Griffin, D., Sams, J.
10.1101/2020.10.29.20204974 — Posted: 2020-11-03
Public Mobility Data Enables COVID-19 Forecasting and Management at Local and Global Scales
Ilin, C., Annan-Phan, S., Tai, X. H., Mehra, S., Hsiang, S. M., Blumenstock, J. E.
10.1101/2020.10.29.20222547 — Posted: 2020-11-03
The Role of Societal Aspects in the Formation of Official COVID-19 Reports: A Data-Driven Analysis
Kurbucz, M. T., Katona, A. I., Lantos, Z., Kosztyan, Z. T.
10.1101/2020.10.28.20221572 — Posted: 2020-11-03
Causal Impacts of Teaching Modality on U.S. COVID-19 Spread in Fall 2020 Semester
Badruddoza, S., Amin, M. D.
10.1101/2020.10.28.20221986 — Posted: 2020-11-03
Preventing COVID-19 Fatalities: State versus Federal Policies
Renne, J.-P., Roussellet, G., Schwenkler, G.
10.1101/2020.10.28.20221952 — Posted: 2020-11-03
Effective community screening for asymptomatic and symptomatic COVID-19 with a fast and extremely low cost COVID-Anosmia Checker tool
Basu, B., Riya, P. A., Issac, J., Parvathy, S., Nair, B. S., Tokdar, P., Kumar, D. S., Kulkarni, P. R., Hanumanram, G., Jagadeesan, M., Suthakaran, P. K., Nair, L. D. V., Vennila, R., Kannan, R., Kaimal, B., Anoop, G. K., Joseph, I., Nair, R., George, S., James, J., Pillai, M. R.
10.1101/2020.10.28.20221200 — Posted: 2020-11-03
U-shaped-aggressiveness of SARS-CoV-2: Period between onset of nonspecific-specific symptoms for COVID-19. A population-based cohort study
Morgenstern-Kaplan, D., Buitano-Tang, B., Martinez-Gil, M., Zaldivar-Perez Pavon, A., Talavera, J. O.
10.1101/2020.10.28.20221697 — Posted: 2020-11-03
A Multi-Factor Risk Model for Severe Covid-19 for Vaccine Prioritization and Monitoring Based on a 15 Million Medicare Cohort
Experton, B., Tetteh, H., Lurie, N., Walker, P., Carroll, C., Elena, A., Hein, C., Schwendiman, B., Burrow, C.
10.1101/2020.10.28.20219816 — Posted: 2020-11-03 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).